Jill Shea

Dr. Jill Shea

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Therapeutic Ultrasound
Verified
Journal Article
Open access
PDF file
NRNatalya Rapoport
Natalya Rapoport
APAllison Payne
Allison Payne
CDChristopher Dillon
Christopher Dillon
JSJill Shea
Jill Shea
CSCourtney Scaife
Courtney Scaife
RGRoohi Gupta
Roohi Gupta
Many aspects of the mechanisms involved in ultrasound-mediated therapy remain obscure. In particular, the relative roles of drug and ultrasound, the effect of the time of ultrasound application, and the effect of tissue heating are not yet clear. The current study was undertaken with the goal to clarify these aspects of the ultrasound-mediated drug delivery mechanism.

26 January 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YSYi Shen
Yi Shen
CZCraig A. Zificsak
Craig A. Zificsak
JSJill Shea
Jill Shea
XLXuegang Lao
Xuegang Lao
OBOana Bollt
Oana Bollt
SKScott K Kuwada
Scott K Kuwada

9 August 2016 in Muscle & Nerve
Verified
Journal Article
Open access
PDF file
PLPratima Labroo
Pratima Labroo
JSJill Shea
Jill Shea
HSHimanshu Sant
Himanshu Sant
BGBruce Gale
Bruce Gale
JAJayant Agarwal
Jayant Agarwal
Introduction: There is a clinical need to improve the outcomes of peripheral nerve regeneration and repair after injury. In addition to its immunosuppressive effects, FK506 (tacrolimus) has been shown to have neuroregenerative properties. To determine biologically relevant local FK506 and growth factor concentrations, we performed anin vitrobioassay using dorsal root ganglion (DRG) from chicken embryos.Methods: Neurite elongation and neurite branching were analyzed microscopically after addition of FK506, glial cell line‐derived neurotrophic factor (GDNF), and nerve growth factor (NGF), each alone and in combination.Results: FK506 induced modest neurite elongation (∼500–800 µm) without improving neurite branching significantly. The combination of FK506 with NGF, GDNF, or both, exerted a potentiating or competitive effect on neurite elongation (∼700–1100 µm) based on dosage and competitive effect on neurite branching (∼0.2–0.4).Conclusions: These results strongly suggest that the interaction of FK506 with GDNF and NGF mediates distinct enhancement of neurite growth.Muscle Nerve55: 570–581, 2017

1 October 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
BDBrett Davis
Brett Davis
SESierra Erickson
Sierra Erickson
SWSusan Wojtalewicz
Susan Wojtalewicz
ASAndrew Simpson
Andrew Simpson
Cameron S MetcalfCameron S Metcalf
Cameron S Metcalf
JAJayant Agarwal
Jayant Agarwal

1 January 2022 in Journal of the Mechanical Behavior of Biomedical Materials
Verified
Journal Article
Closed access
SJSujee Jeyapalina
Sujee Jeyapalina
EHElaine Hillas
Elaine Hillas
JBJames Peter Beck
James Peter Beck
JAJayant Agarwal
Jayant Agarwal
JSJill Shea
Jill Shea

21 April 2021 in IEEE Transactions on Biomedical Engineering
Verified
Journal Article
Closed access
BZBlake E. Zimmerman
Blake E. Zimmerman
SJSara Johnson
Sara Johnson
HOHenrik Odéen
Henrik Odéen
JSJill Shea
Jill Shea
MFMarkus D. Foote
Markus D. Foote
APAllison Payne
Allison Payne
Noninvasive MR-guided focused ultrasound (MRgFUS) treatments are promising alternatives to the surgical removal of malignant tumors. A significant challenge is assessing the viability of treated tissue during and immediately after MRgFUS procedures. Current clinical assessment uses the nonperfused volume (NPV) biomarker immediately after treatment from contrast-enhanced MRI. The NPV has variable accuracy, and the use of contrast agent prevents continuing MRgFUS treatment if tumor coverage is inadequate. This work presents a novel, noncontrast, learned multiparametric MR biomarker that can be used during treatment for intratreatment assessment, validated in a VX2 rabbit tumor model. A deep convolutional neural network was trained on noncontrast multiparametric MR images using the NPV biomarker from follow-up MR imaging (3-5 days after MRgFUS treatment) as the accurate label of nonviable tissue. A novel volume-conserving registration algorithm yielded a voxel-wise correlation between treatment and follow-up NPV, providing a rigorous validation of the biomarker. The learned noncontrast multiparametric MR biomarker predicted the follow-up NPV with an average DICE coefficient of 0.71, substantially outperforming the current clinical standard (DICE coefficient = 0.53). Noncontrast multiparametric MR imaging integrated with a deep convolutional neural network provides a more accurate prediction of MRgFUS treatment outcome than current contrast-based techniques.